AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

Immune checkpoint inhibitors (ICPis) have revolutionized the therapeutic landscape of lung cancer with unprecedented survival results in most of the ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

Recent health updates include the U.S. participating in WHO meetings, UK approval of a Moderna vaccine, a Texas measles ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Dynaprice.com, Inc. today announced definitive agreement and completion of all closing conditions to merge with Dinamo Acquisition Corporation. Through this merger, control of the company passes to a ...

Kiyatec Inc., a leader in advancing patient-specific cancer diagnostics, proudly announces its laboratory's accreditation by the College of American Pathologists (CAP) and receipt of New York State ...